ILF3 inhibits p-AMPK expression to drive non-alcoholic fatty liver disease progression

Figure 1 Elevated ILF3 expression in non-alcoholic fatty liver disease patients and models. A: ILF3 expression in serum of non-alcoholic fatty liver disease (NAFLD) patients; B: Serum ILF3 expression according to NAFLD severity; C and D: Elevated ILF3 expression in rising Oleic acid mixture (OA) concentration treated in HepG2 cells; E and F: Oil Red O staining showing increased lipid deposition in OA-treated HepG2 cells and mice liver tissues; G and H: Elevated ILF3 expression in NAFLD mice model detected by qPCR and Western blotting. All data are presented as the mean ± SD. ^bP < 0.01; ^cP < 0.001; NAFLD: Non-alcoholic fatty liver disease; SCD: Standard chow diet; HFD: High-fat diet.